journal article·2023-12-31Open access

Immunogenic antitumor potential of Prakasine nanoparticles in zebrafish by gene expression stimulation

Prakash S. K.

Abstract

In this study, non-toxic mercury nanoparticle was synthesized as per "Prakash theory of metal drugs" and nanoparticle's characters has been demonstrated by employing several nanotechnological tools including XPS, XRD, EDAX. The size of the Prakasine nanoparticles (PRK-NP) ranged from 90-100 nm, confirmed using TEM, SEM, DLS and along with zeta potential of -29.5 mV before storage and -8.5 mV after storage. The FTIR provided information regarding the nanoparticle capping and functional groups. The study was further elaborated for determining PRK-NPs toxicity, genotoxicity, in-vivo toxicity, immunological anti-tumour activity, immunogenicity potential, gene expression profiling and confirmed by MTT and apoptosis assays, cancer zebrafish model studies and WBC proliferation assay. PRK-NPs revealed no cytotoxicity where cell viability was observed 99% in L6 mouse fibroblasts and 99% in MCF-7 cell lines. Also, the cell viability was to be 89.47% at a very high concentration of 320 µg/ml in HEK 293 cells. The PRK-NPs significantly reduced the tumour in zebrafish at dose of 90 μg/g by up regulating IL-1α, IL-1β, IL-2-ITK, IL-6, IL-8, IL-12, TNF-α and IFN-γ, and down regulating IL-4, IL-5, IL-10 and TGF-β compared to untreated controls without any adverse effects and toxicity. Thus, the current study beholds anticipation PRK-NPs may play a vital role in therapeutic.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticles: synthesis and applications · Phagocytosis and Immune Regulation · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Naval AIDS Research Centre, Namakkal, Tamil Nadu, India

References (62)

Show source-provided references
1. 10.1126/science.aan250710.1126/science.aan2507 ↗
2. 10.3322/caac.2159010.3322/caac.21590 ↗
3. 10.1007/s00432-016-2179-310.1007/s00432-016-2179-3 ↗
4. 10.1038/nnano.2009.15310.1038/nnano.2009.153 ↗
5. 10.1016/j.smim.2017.09.01110.1016/j.smim.2017.09.011 ↗
6. 10.1038/nri348810.1038/nri3488 ↗
7. Conway A · Nat Nanotechnol · 2013 · 8 · 83110.1038/nnano.2013.205 ↗
8. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
9. 10.1038/nrd261410.1038/nrd2614 ↗
10. 10.1038/nnano.2017.5710.1038/nnano.2017.57 ↗
11. 10.1038/nbt.333010.1038/nbt.3330 ↗
12. 10.1038/nmat378010.1038/nmat3780 ↗
13. 10.1038/s41565-019-0626-410.1038/s41565-019-0626-4 ↗
14. Wang J · Nat Nanotechnol · 2018 · 13 · 107810.1038/s41565-018-0274-0 ↗
15. 10.1038/s41565-020-0643-310.1038/s41565-020-0643-3 ↗
16. Huang Y · Nat Commun · 2020 · 11 · 62210.1038/s41467-020-14425-7 ↗
17. Chakraborty C · J Nanobiotechnology · 2016 · 14 · 6510.1186/s12951-016-0217-6 ↗
18. 10.1126/science.aad219710.1126/science.aad2197 ↗
19. Javed I · Nat Commun · 2019 · 10 · 378010.1038/s41467-019-11762-0 ↗
20. 10.1016/j.jconrel.2019.08.02210.1016/j.jconrel.2019.08.022 ↗
21. 10.1002/jat.372110.1002/jat.3721 ↗
22. Langenau DM · Nat Rev Immunol · 2005 · 5 · 30710.1038/nri1590 ↗
23. Leslie M. · Science · 2017 · 357 · 74510.1126/science.357.6353.745 ↗
24. Prakash SK. · Indian Vet J · 2017 · 94 · 11
25. 10.1002/smll.20120076010.1002/smll.201200760 ↗
26. 10.1021/es062121q10.1021/es062121q ↗
27. 10.1103/PhysRevB.9.60010.1103/PhysRevB.9.600 ↗
28. Marimuthu G · J Nanopart Res · 2012 · 14 · 71010.1007/s11051-011-0710-7 ↗
29. Paulkumar K · ScientificWorld Journal · 2014 · 2014 · 82989410.1155/2014/829894 ↗
30. Lupusoru RV · Sci Rep · 2020 · 10 · 659110.1038/s41598-020-63245-8 ↗
31. Androussi Y. · Philos Mag Lett · 1999 · 79 · 20110.1080/095008399177444 ↗
32. 10.1208/s12249-019-1334-y10.1208/s12249-019-1334-y ↗
33. 10.1080/03639045.2017.131022310.1080/03639045.2017.1310223 ↗
34. 10.1089/dna.2012.194610.1089/dna.2012.1946 ↗
35. 10.1016/j.nano.2015.09.00210.1016/j.nano.2015.09.002 ↗
36. Wallace CK · J Am Assoc Lab Anim Sci · 2018 · 57 · 58
37. 10.1080/01635581.2018.150232710.1080/01635581.2018.1502327 ↗
38. 10.1007/s10875-012-9836-310.1007/s10875-012-9836-3 ↗
39. 10.3390/cells811141310.3390/cells8111413 ↗
40. Olsson K · Leukemia · 1999 · 13 · 183310.1038/sj.leu.2401575 ↗
41. Antiabong JF · Vet World · 2016 · 9 · 93510.14202/vetworld.2016.935-939 ↗
42. Hsu‐Kim H · Environ Sci Technol · 2005 · 39 · 403510.1021/es050013i ↗
43. 10.1002/978111852099410.1002/9781118520994 ↗
44. 10.1080/00958972.2012.76264410.1080/00958972.2012.762644 ↗
45. Zhang J · Mater Res Bull · 2004 · 39 · 224110.1016/j.materresbull.2004.08.001 ↗
46. 10.1109/ICONSET.2011.616792210.1109/ICONSET.2011.6167922 ↗
47. Carotenuto G · MATS · 2008 · 1 · 110.2174/1874464810801010001 ↗
48. Wang DS · Chemistry · 2009 · 15 · 187010.1002/chem.200801815 ↗
49. 10.1039/B9NR00194H10.1039/B9NR00194H ↗
50. 10.1039/C4TB01708K10.1039/C4TB01708K ↗
51. 10.2174/092986732466617081015491710.2174/0929867324666170810154917 ↗
52. 10.1002/mp.1310010.1002/mp.13100 ↗
53. 10.1080/21691401.2019.160453310.1080/21691401.2019.1604533 ↗
54. Norouzi M · Sci Rep · 2020 · 10 · 1129210.1038/s41598-020-68017-y ↗
55. 10.1038/s41423-020-0488-610.1038/s41423-020-0488-6 ↗
56. Brunton LL · 2006
57. 10.3390/cancers304385610.3390/cancers3043856 ↗
58. Roff SR · Front Immunol · 2014 · 4 · 498
59. Januškevica I · Proc Latv Acad Sci B · 2016 · 70 · 211
60. Prakash SK. · Virol Antivir Res · 2020 · 9
61. Prakash SK. Phytochemical therapy as a possible cure for asymptomatic AIDS patients [dissertation]. India: Bharathidasan University; 2010.
62. Prakash SK. Immunological and virological effects of Prakasine nanomedicine in HIV eradication: a preliminary study. Fifth Eastern Europe and Central Asia AIDS conference; 2016 Mar 23–25, Moscow.